CD40 and colitis: Recently, a novel selective RORγt (VPR-254) inhibitor was shown to reduce the production of key pro-inflammatory cytokines in an Anti-CD40 antibody-induced mouse model of colitis, implying that inhibition of RORγt can also suppress inflammation caused by innate immune-associated cytokines (114).